Intellia Therapeutics Inc (NTLA) is gearing up for another turning point as it hit the volume of 1.94 million

Intellia Therapeutics Inc (NASDAQ: NTLA) kicked off on Friday, up 1.59% from the previous trading day, before settling in for the closing price of $8.18. Over the past 52 weeks, NTLA has traded in a range of $5.90-$28.18.

During the last 5-year period, the sales growth of Healthcare Sector giant was 15.68%. While this was happening, its average annual earnings per share was recorded 10.69%. With a float of $97.42 million, this company’s outstanding shares have now reached $102.03 million.

Let’s determine the extent of company efficiency that accounts for 403 employees. In terms of profitability, gross margin is 91.17%, operating margin of -923.1%, and the pretax margin is -896.77%.

Intellia Therapeutics Inc (NTLA) Insider Activity

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Intellia Therapeutics Inc is 5.89%, while institutional ownership is 92.60%. The most recent insider transaction that took place on Mar 04 ’25, was worth 6,104. In this transaction EVP, Chief Technical Officer of this company sold 679 shares at a rate of $8.99, taking the stock ownership to the 95,369 shares. Before that another transaction happened on Mar 04 ’25, when Company’s EVP, General Counsel sold 2,572 for $8.99, making the entire transaction worth $23,122. This insider now owns 111,925 shares in total.

Intellia Therapeutics Inc (NTLA) Earnings and Forecasts

According to the Wall Street analysts, stocks earnings will be around 10.69% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 23.52% during the next five years compared to -20.04% drop over the previous five years of trading.

Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators

Take a look at Intellia Therapeutics Inc’s (NTLA) current performance indicators. Last quarter, stock had a quick ratio of 5.77. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.86.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.25, a number that is poised to hit -1.28 in the next quarter and is forecasted to reach -4.43 in one year’s time.

Technical Analysis of Intellia Therapeutics Inc (NTLA)

Looking closely at Intellia Therapeutics Inc (NASDAQ: NTLA), its last 5-days average volume was 2.9 million, which is a drop from its year-to-date volume of 3.37 million. As of the previous 9 days, the stock’s Stochastic %D was 69.64%. Additionally, its Average True Range was 0.68.

During the past 100 days, Intellia Therapeutics Inc’s (NTLA) raw stochastic average was set at 23.84%, which indicates a significant decrease from 80.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 87.02% in the past 14 days, which was higher than the 81.41% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $8.89, while its 200-day Moving Average is $15.38. However, in the short run, Intellia Therapeutics Inc’s stock first resistance to watch stands at $8.46. Second resistance stands at $8.60. The third major resistance level sits at $8.88. If the price goes on to break the first support level at $8.04, it is likely to go to the next support level at $7.76. Should the price break the second support level, the third support level stands at $7.62.

Intellia Therapeutics Inc (NASDAQ: NTLA) Key Stats

The company with the Market Capitalisation of 860.23 million has total of 103,517K Shares Outstanding. Its annual sales at the moment are 57,880 K in contrast with the sum of -519,020 K annual income. Company’s last quarter sales were recorded 12,870 K and last quarter income was -128,900 K.